R
Rowan G. Walker
Researcher at Alfred Hospital
Publications - 218
Citations - 8277
Rowan G. Walker is an academic researcher from Alfred Hospital. The author has contributed to research in topics: Transplantation & Kidney disease. The author has an hindex of 48, co-authored 218 publications receiving 7642 citations. Previous affiliations of Rowan G. Walker include Royal Women's Hospital & University of Melbourne.
Papers
More filters
Journal ArticleDOI
Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1
TL;DR: DNA linkage among subjects from 128 sibships within 18 PKD1 families was used as the basis for an assessment of ultrasound sensitivity, and the presence of at least two renal cysts in individuals at risk and younger than 30 years may be regarded as sufficient to establish a diagnosis.
Journal ArticleDOI
The burden of kidney disease: Improving global outcomes
Garabed Eknoyan,Norbert Lameire,Rashad S. Barsoum,Kai-Uwe Eckardt,Adeera Levin,Nathan W. Levin,Francesco Locatelli,Alison M. MacLeod,Raymond Vanholder,Rowan G. Walker,Haiyan Wang +10 more
TL;DR: A new initiative "Kidney Disease: Improving Global Outcomes" has been established, its stated mission is to improve the care and outcomes of kidney disease patients worldwide through promoting coordination, collaboration and integration of initiatives to develop and implement clinical practice guidelines.
Journal ArticleDOI
A Randomized, Multicenter Study of Steroid Avoidance, Early Steroid Withdrawal or Standard Steroid Therapy in Kidney Transplant Recipients
Flavio Vincenti,Francesco Paolo Schena,S. Paraskevas,Ingeborg A. Hauser,Rowan G. Walker,Josep M. Grinyó +5 more
TL;DR: For standard‐risk renal transplant patients receiving CsA‐ME, EC‐MPS and basiliximab, steroid withdrawal by the end of week 1 achieves similar 1‐year renal function to a standard‐steroids regimen, and may be more desirable than complete steroid avoidance.
Journal ArticleDOI
Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients.
H. Tedesco Silva,Diane M. Cibrik,Thomas D. Johnston,E. Lackova,K. Mange,C. Panis,Rowan G. Walker,Z. Wang,Gazi B. Zibari,Yu Seun Kim +9 more
TL;DR: The use of everolimus with progressive reduction in CsA exposure, up to 60% at 1 year, resulted in similar efficacy and renal function compared with standard‐exposure Cs a plus MPA.
Journal ArticleDOI
Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)
Katrin Uhlig,Alison M. MacLeod,Jonathan C. Craig,Joseph Lau,Andrew S. Levey,Adeera Levin,Louise Moist,E Steinberg,Rowan G. Walker,Christoph Wanner,Norbert Lameire,Garabed Eknoyan +11 more
TL;DR: Adaptations of the GRADE approach are presented to address some issues pertinent to the field of nephrology, including the need to extrapolate from studies performed predominantly in patients without kidney disease, and theneed to use qualitative summaries of effects when it is not feasible to quantitatively summarize them.